Roche Holding AG (0QOK) Share Forecast & Price Target

34 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QOK Analyst Ratings

Moderate Buy

6 Buy

4 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Roche

Holding AG

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QOK Stock 12 Month Forecast

Average Price Target

CHF389.68

▲(10.47% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Roche Holding AG in the last 3 months. The average price target is CHF389.68 with a high forecast of CHF500.00 and a low forecast of CHF250.00. The average price target represents a 10.47% change from the last price of CHF352.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"249":"CHF249","312":"CHF312","375":"CHF375","438":"CHF438","501":"CHF501"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF500.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":389.6818181818182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF389.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF250.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[249,312,375,438,501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,349,360.61538461538464,372.2307692307692,383.84615384615387,395.46153846153845,407.0769230769231,418.6923076923077,430.3076923076923,441.9230769230769,453.53846153846155,465.15384615384613,476.7692307692308,488.38461538461536,{"y":500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,349,352.1293706293706,355.2587412587413,358.3881118881119,361.5174825174825,364.6468531468532,367.7762237762238,370.9055944055944,374.034965034965,377.1643356643357,380.2937062937063,383.4230769230769,386.5524475524476,{"y":389.6818181818182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,349,341.38461538461536,333.7692307692308,326.15384615384613,318.53846153846155,310.9230769230769,303.3076923076923,295.6923076923077,288.0769230769231,280.46153846153845,272.84615384615387,265.2307692307692,257.61538461538464,{"y":250,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":271.93,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":251.172,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":299.478,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":318.388,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":344.022,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":352.121,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.796,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.206,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":323.416,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.705,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355.98,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":346.138,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF500.00

Average Price TargetCHF389.68

Lowest Price TargetCHF250.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

CHF500

Buy

41.74%

Upside

Reiterated

10/28/26

Deutsche Bank Sticks to Their Buy Rating for Roche Holding AG (RHHVF)

Trung Huynh

RBC Capital

CHF400

Buy

13.39%

Upside

Reiterated

10/27/26

Roche Holding AG (RHHVF) Receives a Buy from RBC Capital

Richard Vosser

J.P. Morgan

CHF325→CHF335

Hold

-5.03%

Downside

Reiterated

10/26/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Establishment Labs Holdings (NASDAQ: ESTA) and Roche Holding AG (Other OTC: RHHVF)

Matthew Weston

UBS

CHF376

Buy

6.59%

Upside

Reiterated

10/23/26

Analysts Are Bullish on Top Healthcare Stocks: Medios AG (MEDOF), Roche Holding AG (RHHVF)

Michael Leuchten

Jefferies

CHF250

Sell

-29.13%

Downside

Reiterated

10/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (Other OTC: RHHVF), Thermo Fisher (NYSE: TMO) and Argenx Se (NASDAQ: ARGX)

James Quigley

Goldman Sachs

CHF376→CHF391

Hold

10.84%

Upside

Reiterated

10/23/26

Goldman Sachs Remains a Hold on Roche Holding AG (RHHVF)

Luisa Hector

Berenberg Bank

CHF350

Hold

-0.78%

Downside

Reiterated

10/21/26

Berenberg Bank Reaffirms Their Hold Rating on Roche Holding AG (RHHVF)

Unknown Analyst

Oddo BHF

Not Ranked

Oddo BHF

CHF300→CHF440

Buy

24.73%

Upside

Upgraded

10/20/26

Roche upgraded to Outperform from Underperform at Oddo BHFRoche upgraded to Outperform from Underperform at Oddo BHF

Justin Smith

Bernstein

CHF434.5

Buy

23.18%

Upside

Reiterated

10/06/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Rezolute (NASDAQ: RZLT) and Coya Therapeutics, Inc. (NASDAQ: COYA)

Rajesh Kumar

HSBC

CHF365→CHF380

Hold

7.73%

Upside

Reiterated

09/10/26

Roche price target raised to CHF 380 from CHF 365 at HSBCRoche price target raised to CHF 380 from CHF 365 at HSBC

James Gordon CFA

Barclays

CHF410→CHF430

Buy

21.90%

Upside

Reiterated

09/08/26

Barclays Sticks to Their Buy Rating for Roche Holding AG (RHHVF)

Hans Engel

Erste Group

―

Hold

―

Reiterated

05/04/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Sarita Kapila

Morgan Stanley

CHF295

Hold

-16.37%

Downside

Upgraded

04/24/26

Roche upgraded to Equal Weight from Underweight at Morgan StanleyRoche upgraded to Equal Weight from Underweight at Morgan Stanley

David Evans

Kepler Capital

CHF415

Buy

17.65%

Upside

Reiterated

04/23/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Sanofi (Other OTC: SNYNF)

Graham Parry

Citi

―

Buy

―

Reiterated

03/10/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), BioNTech SE (NASDAQ: BNTX) and Skye Bioscience (NASDAQ: SKYE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

CHF500

Buy

41.74%

Upside

Reiterated

10/28/26

Deutsche Bank Sticks to Their Buy Rating for Roche Holding AG (RHHVF)

Trung Huynh

RBC Capital

CHF400

Buy

13.39%

Upside

Reiterated

10/27/26

Roche Holding AG (RHHVF) Receives a Buy from RBC Capital

Richard Vosser

J.P. Morgan

CHF325→CHF335

Hold

-5.03%

Downside

Reiterated

10/26/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Establishment Labs Holdings (NASDAQ: ESTA) and Roche Holding AG (Other OTC: RHHVF)

Matthew Weston

UBS

CHF376

Buy

6.59%

Upside

Reiterated

10/23/26

Analysts Are Bullish on Top Healthcare Stocks: Medios AG (MEDOF), Roche Holding AG (RHHVF)

Michael Leuchten

Jefferies

CHF250

Sell

-29.13%

Downside

Reiterated

10/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (Other OTC: RHHVF), Thermo Fisher (NYSE: TMO) and Argenx Se (NASDAQ: ARGX)

James Quigley

Goldman Sachs

CHF376→CHF391

Hold

10.84%

Upside

Reiterated

10/23/26

Goldman Sachs Remains a Hold on Roche Holding AG (RHHVF)

Luisa Hector

Berenberg Bank

CHF350

Hold

-0.78%

Downside

Reiterated

10/21/26

Berenberg Bank Reaffirms Their Hold Rating on Roche Holding AG (RHHVF)

Unknown Analyst

Oddo BHF

Not Ranked

Oddo BHF

CHF300→CHF440

Buy

24.73%

Upside

Upgraded

10/20/26

Roche upgraded to Outperform from Underperform at Oddo BHFRoche upgraded to Outperform from Underperform at Oddo BHF

Justin Smith

Bernstein

CHF434.5

Buy

23.18%

Upside

Reiterated

10/06/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Rezolute (NASDAQ: RZLT) and Coya Therapeutics, Inc. (NASDAQ: COYA)

Rajesh Kumar

HSBC

CHF365→CHF380

Hold

7.73%

Upside

Reiterated

09/10/26

Roche price target raised to CHF 380 from CHF 365 at HSBCRoche price target raised to CHF 380 from CHF 365 at HSBC

James Gordon CFA

Barclays

CHF410→CHF430

Buy

21.90%

Upside

Reiterated

09/08/26

Barclays Sticks to Their Buy Rating for Roche Holding AG (RHHVF)

Hans Engel

Erste Group

―

Hold

―

Reiterated

05/04/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Sarita Kapila

Morgan Stanley

CHF295

Hold

-16.37%

Downside

Upgraded

04/24/26

Roche upgraded to Equal Weight from Underweight at Morgan StanleyRoche upgraded to Equal Weight from Underweight at Morgan Stanley

David Evans

Kepler Capital

CHF415

Buy

17.65%

Upside

Reiterated

04/23/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Sanofi (Other OTC: SNYNF)

Graham Parry

Citi

―

Buy

―

Reiterated

03/10/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), BioNTech SE (NASDAQ: BNTX) and Skye Bioscience (NASDAQ: SKYE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AORTArtivion

MDWDMediwound

IMUXImmunic

RZLTRezolute

DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roche Holding AG

3 Months

Matthew WestonUBS

Success Rate

12/15 ratings generated profit

Average Return

+8.37%

Copying Matthew Weston's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +8.37% per trade.

1 Year

Matthew WestonUBS

Success Rate

15/15 ratings generated profit

Average Return

+31.08%

Copying Matthew Weston's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.08% per trade.

2 Years

David EvansKepler Capital

Success Rate

19/19 ratings generated profit

Average Return

+52.48%

Copying David Evans's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +52.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QOK Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QOK has received 14 Buy Ratings, 11 Hold Ratings, and 3 Sell Ratings. 0QOK average Analyst price target in the past 3 months is 389.68.

Each month's total comprises the sum of three months' worth of ratings.

0QOK Financial Forecast

0QOK Earnings Forecast

Next quarter’s earnings estimate for 0QOK is CHF9.62 with a range of CHF9.15 to CHF10.48. The previous quarter’s EPS was CHF10.85. 0QOK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0QOK has Performed in-line its overall industry.

0QOK Sales Forecast

Next quarter’s sales forecast for 0QOK is CHF16.31B with a range of CHF16.05B to CHF16.59B. The previous quarter’s sales results were CHF30.36B. 0QOK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0QOK has Performed in-line its overall industry.

0QOK Stock Forecast FAQ

What is GB:0QOK’s average 12-month price target, according to analysts?

Based on analyst ratings, Roche Holding AG’s 12-month average price target is 389.68.

What is GB:0QOK’s upside potential, based on the analysts’ average price target?

Roche Holding AG has 10.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Roche Holding AG a Buy, Sell or Hold?

Roche Holding AG has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 4 hold ratings and 1 sell ratings.

What is Roche Holding AG’s share price target?

The average share price target for Roche Holding AG is 389.68. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF500.00 ,and the lowest forecast is CHF250.00. The average share price target represents 10.47% Increase from the current price of CHF352.75.

What do analysts say about Roche Holding AG?

Roche Holding AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Roche Holding AG?

To buy shares of GB:0QOK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Roche Holding AG (0QOK) Share Forecast & Price Target

0QOK Analyst Ratings

0QOK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Roche Holding AG

0QOK Analyst Recommendation Trends

0QOK Financial Forecast

0QOK Earnings Forecast

0QOK Sales Forecast

0QOK Stock Forecast FAQ

Detailed List of Analyst Forecasts